Business Wire

OCTASIC-INC

17.9.2020 04:02:10 CEST | Business Wire | Press release

Share
Panasonic and Octasic Extend sXGP Collaboration to 5G/Beyond 5G

Panasonic Corporation, a world-leading provider of diverse electronics technologies, B2B, communications and wireless solutions, and Octasic Inc., an innovation leader in low-power programmable processors for wireless and multimedia applications, today announced the enhancement of their ongoing collaboration to develop shared eXtended Global Platform (sXGP) solutions to include 5G and Beyond 5G based wireless network products, especially for mission-critical applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005982/en/

Panasonic and Octasic will combine resources and expertise to develop high-performance, high reliability, and low-latency Small Cell solutions for the cellular IoT space, applied to B2B, Non-Terrestrial Networks in Avionics and other mission-critical verticals based on Octasic's OCT3032 System-on-Chip.

The Collaboration on sXGP

Panasonic has developed an sXGP wireless base station that makes full use of the OCT3032's embedded Opus DSP technology and realizes stable communication even in environments with high interference in unlicensed bands.

The 5G Collaboration

The expanded collaboration addresses the challenging requirements of developing a new class of Small Cells to be deployed in a wireless base station platform that contributes to mission-critical applications for advanced IoT environments and non-terrestrial operations toward 5G and Beyond 5G.

Octasic’s programmable processor platform delivers on the low power requirements of Panasonic Small Cell designs and accelerates development and support of multiple air interfaces from sXGP to 3GPP. More importantly it addresses the need for deterministic air interface design to meet the challenges of implementing an ultra-reliable low-latency solution in diverse environments from private campus-wide networks, to machine or robotic communication in warehouses, to aircraft systems.

Panasonic promotes the development of Ultra-Reliable and Low-Latency Communications (URLLC) functions that comply with both 3GPP and Non-Terrestrial Network (NTN) technologies and provides Octasic with engineering expertise and resources. In addition, Panasonic will accelerate digital transformation for itself and its customers demonstrating various IoT-related applications inside and outside the company.

Hideo Ohara, Director of Panasonic Technology Department, emphasized, “We are leveraging Octasic’s OCT3032 System-on-Chip, development tools, and 4G/5G software to develop and deploy differentiated sXGP, 4G, and 5G Small Cell network products that deliver on our world-leading technical requirements for high performance, highly reliable, low latency, and low power Small Cell network products. We are delighted to advance the evolution of society with such unique systems that are the culmination of our years of technological collaboration with Octasic.”

Fabio Gambacorta, Global VP Business Development and Sales at Octasic emphasized, “Offering a world-leading System-on-Chip solution for Small Cell designs does not happen by chance; it is critical to partner with an innovative wireless network OEM like Panasonic. Octasic is proud to collaborate on not only the development of Panasonic’s first sXGP network products, but to expand this collaboration to encompass future solutions for 3GPP-compliant 4G and 5G networks, especially those requiring high reliability, low latency, and low power.”

For more information about the OCT3032 SoC and its evaluation and development platforms, please contact pr@octasic.com or visit www.octasic.com/product/oct3032w/ .

About Octasic Inc.

Founded in 1998 and headquartered in Canada, Octasic develops innovative programmable processors for mobile wireless markets such as proprietary 4G/5G-based networks. Octasic’s Opus-based processor technology, programming tools, software and reference code reduce costs, mitigate risk, accelerate time-to-market, and allow developers to focus engineering resources on their areas of differentiation. With 20 years of technology development in low-power programmable System-on-Chip solutions, Octasic products deliver a low-power, low-latency “5G Small Cell on a Chip” for both commercial and private networks. For more information, please visit http://www.octasic.com/ .

About Panasonic Corporation

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .

For media inquiries, please contact Global Communications Department:

https://news.panasonic.com/global/contacts/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye